In a discussion moderated by Peter Salgo, MD, panelists Jeffrey Weber, MD, PhD, Michael Kolodziej, MD, and Daniel J. George, MD, share their insights and perspectives about cancer immunotherapy in the managed care setting.
Dr Salgo opens up the discussion with some facts about cancer and claims that cancer is currently recognized as the “global pandemic” that killed more than 600,000 US persons in 2012 alone. Despite its deep history, the potential of cancer immunotherapy has only been tapped into recently. Due to the high costs of treatment, cancer immunotherapy is debatable. Dr Salgo explains that a majority of the immunotherapy drugs approved by the US Food and Drug Administration cost over $100,000 per year.
Regardless of these costs, Dr George believes we need to take advantage of this therapy option, as it has proved more effective than standard therapy options such as chemotherapy and radiation when treating several types of cancer.
Dr George continues the discussion with an explanation about how cancer immunotherapy works. Dr Weber concludes by defining immunotherapy as a “targeted therapy,” and cites Provenge, a targeted therapy cancer vaccine, as an example.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More